Jason Cole, MD
Cardiovascular Disease · Mobile, ALNPI 1083666705
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,406 of the $8,689 with a category attached, or 73.7%. Cleerly, Inc. accounts for 74.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $6,390, more than ten times the $66 reported in 2019.
Across 36 payments — averaging $241.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cleerly, Inc.$6K
- Heartflow, Inc.$850
- GE HealthCare$810
- Johnson & Johnson$154
- Esperion Therapeutics, Inc.$125
- Boehringer Ingelheim$103
- plus $200 from 5 others
Across 21 payments — averaging $5829.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$100K
- Heartflow, Inc.$22K
What the payments were for
- Consulting fees$6,40674%
- Travel & lodging$1,15313%
- Food & beverage$1,13013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cleerly, Inc. | 4 | $6,446 |
| Heartflow, Inc. | 3 | $850 |
| GE HealthCare | 5 | $810 |
| Johnson & Johnson | 10 | $154 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Boehringer Ingelheim | 5 | $103 |
| Medtronic | 2 | $84 |
| Siemens Medical Solutions USA, Inc. | 2 | $47 |
| Abbott | 2 | $36 |
| Amgen | 1 | $18 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$756
- NEXLIZET$125
- NEXLETOL$125
- Cleerly Ischemia$104
- Cleerly Labs$104
How this compares
$8,689 in reported general payments places this provider in the 75th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 465 | $403,008 |
| XareltoRivaroxaban | 161 | $168,886 |
| EntrestoSacubitril/Valsartan | 166 | $158,186 |
| FarxigaDapagliflozin Propanediol | 40 | $26,416 |
| Ranolazine ErRanolazine | 81 | $12,102 |
| Repatha SureclickEvolocumab | 14 | $12,002 |
| Atorvastatin Calcium | 479 | $6,509 |
| Carvedilol | 505 | $4,470 |
| Icosapent Ethyl | 16 | $4,367 |
| Nitroglycerin | 99 | $3,583 |
| Metoprolol Succinate | 217 | $3,289 |
| Rosuvastatin Calcium | 193 | $2,955 |
| ClopidogrelClopidogrel Bisulfate | 204 | $2,482 |
| Clonidine | 13 | $2,482 |
| SotalolSotalol Hcl | 64 | $2,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $403,008465 claims |
| Johnson & JohnsonXarelto | $154 | $168,886161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Mobile
- Dennis ThomasMobile$894K
- Michael RihnerMobile$13K
- Ghulam AwanMobile$9K
- David FienoAlabaster$421K
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.